Jasper Therapeutics (NASDAQ:JSPR) Downgraded by Wall Street Zen to “Sell”

Posted by Latisha Jones on Sep 19th, 2026

Wall Street Zen lowered shares of Jasper Therapeutics (NASDAQ:JSPR – Free Report) from a hold rating to a sell rating in a research report report published on Saturday,Wall Street Zen reports.

Several other research firms have also recently commented on JSPR. Weiss Ratings restated a “sell (e+)” rating on shares of Jasper Therapeutics in a report on Friday, July 17th. Piper Sandler started coverage on shares of Jasper Therapeutics in a report on Wednesday, August 12th. They set an “overweight” rating and a $2.00 price objective on the stock. Finally, HC Wainwright reissued a “buy” rating on shares of Jasper Therapeutics in a research report on Tuesday, August 18th. Six research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Jasper Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $8.17.

Check Out Our Latest Stock Analysis on JSPR

Jasper Therapeutics Stock Down 2.6%

Shares of Jasper Therapeutics stock opened at $0.62 on Friday. Jasper Therapeutics has a fifty-two week low of $0.32 and a fifty-two week high of $2.69. The firm has a market cap of $20.56 million, a PE ratio of -0.39 and a beta of 3.04. The business’s fifty day moving average is $0.71 and its two-hundred day moving average is $0.79.

Jasper Therapeutics (NASDAQ:JSPR – Get Free Report) last announced its quarterly earnings data on Friday, August 14th. The company reported ($0.10) EPS for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.17. Equities research analysts anticipate that Jasper Therapeutics will post -1.14 EPS for the current year.

About Jasper Therapeutics

(Get Free Report)

Jasper Therapeutics, Inc is a clinical-stage biotechnology company developing antibody therapies for diseases driven by mast cells and for conditions requiring the controlled depletion of blood-forming stem cells. The company’s research is centered on targeting c-Kit, a receptor involved in the survival and development of mast cells and hematopoietic stem and progenitor cells.

Jasper’s lead product candidate is briquilimab, formerly known as JSP191, an investigational monoclonal antibody designed to block c-Kit activity.